<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00557518</url>
  </required_header>
  <id_info>
    <org_study_id>ALT-711-0424</org_study_id>
    <nct_id>NCT00557518</nct_id>
  </id_info>
  <brief_title>Study of Alagebrium in Patients With Insulin-Dependent Type 1 Diabetes and Microalbuminuria</brief_title>
  <official_title>A Randomized, Placebo-Controlled Trial of Alagebrium in Patients With Insulin-Dependent Type 1 Diabetes and Microalbuminuria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Synvista Therapeutics, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Juvenile Diabetes Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Synvista Therapeutics, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Based upon the preclinical evidence in models of diabetic nephropathy under conditions
      approximating both type I and II diabetes, treatment with alagebrium appears to have
      favorable and advantageous effects on the biochemical, structural, pathological and
      functional hallmarks of diabetic nephropathy. The renoprotective effects of alagebrium in
      preclinical models favor the evaluation of this drug in patients with type I diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a double-blind, randomized, placebo-controlled, parallel design trial enrolling
      80 patients (2x40) with Type 1 diabetes and microalbuminuria. Patients will be randomized to
      either 200 mg Alagebrium twice daily or placebo for a period of 24 weeks after an 8 week
      run-in period. There will be a 8 week run-out period. All patients will receive ramipril
      during the entire study period. Efficacy measurements will be performed at baseline, at 12
      weeks and at the end of the study. Measurements for albumin:creatinine ratio(mg/g), plasma
      renin level, collagen markers, AGE related markers and 24 hour blood pressure measurements
      will also be determined. A total of 9 visits will be performed during the entire study.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study has been terminated early due to financial constraints.
  </why_stopped>
  <start_date>November 2007</start_date>
  <completion_date type="Anticipated">November 2009</completion_date>
  <primary_completion_date type="Anticipated">September 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in albumin excretion rate (Âµg/min)</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Albumin:creatinine ratio(mg/g), plasma renin level, collagen markers, AGE related markers, 24 hour blood pressure determinations</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <condition>Diabetic Nephropathy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alagebrium</intervention_name>
    <description>200 mg bid</description>
    <arm_group_label>1</arm_group_label>
    <other_name>ALT-711</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>bid</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Insulin-dependent type 1 diabetes

          -  Age 18-65 years

          -  Diagnosis of established microalbuminuria

          -  Blood pressure &lt;140 mm Hg, diastolic blood pressure &lt;90 mm Hg

          -  HbA1c &lt;10%

        Exclusion Criteria:

          -  Body mass index &gt;40 kg/m2

          -  Cardiovascular event within 6 months prior to screening

          -  History of acute myocardial infarction within 12 months prior to screening

          -  Serum creatinine &gt;1.5 mg/dL

          -  Receiving chronic nonsteroidal anti-inflammatory therapy

          -  Receiving antihypertensive therapy except for angiotensin converting enzyme inhibitors
             or angiotensin receptor blockers

          -  Any significant systemic illnesses,medical conditions or abnormal laboratory values
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark E Cooper, MBBS, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Baker Heart Research Institute, Melbourne, Australia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Diabetes Institute</name>
      <address>
        <city>Caulfield</city>
        <state>Victoria</state>
        <zip>3162</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Clinical and Biomedical Science Myers House</name>
      <address>
        <city>Geelong</city>
        <state>Victoria</state>
        <zip>3220</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Health</name>
      <address>
        <city>Heidelburg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Steno Diabetes Center</name>
      <address>
        <city>Gentofte</city>
        <zip>DK-2820</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 12, 2007</study_first_submitted>
  <study_first_submitted_qc>November 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2007</study_first_posted>
  <last_update_submitted>January 29, 2009</last_update_submitted>
  <last_update_submitted_qc>January 29, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 30, 2009</last_update_posted>
  <responsible_party>
    <name_title>Mark Cooper</name_title>
    <organization>Baker Heart Research Institute, Melbourne, Australia</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

